Aurobindo Pharma announced on Tuesday that it will produce and supply the long-acting injectable HIV treatment, cabotegravir, across 133 countries.
The Hyderabad-based pharmaceutical company has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare.
This agreement enables Aurobindo to make the drug available in multiple low- and middle-income countries, significantly expanding access to advanced HIV treatment options.